Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free CDXS Stock Alerts

Codexis (CDXS) Competitors

Codexis logo
$2.58 -0.08 (-3.01%)
As of 04:00 PM Eastern
Compare

CDXS vs. ZBIO, GERN, MNKD, OPK, and IRWD

Should you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Zenas BioPharma (ZBIO), Geron (GERN), MannKind (MNKD), OPKO Health (OPK), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry.

How does Codexis compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Zenas BioPharma presently has a consensus target price of $44.14, suggesting a potential upside of 129.08%. Codexis has a consensus target price of $5.00, suggesting a potential upside of 93.80%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Zenas BioPharma is more favorable than Codexis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zenas BioPharma
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44
Codexis
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Zenas BioPharma has a net margin of 0.00% compared to Codexis' net margin of -62.47%. Zenas BioPharma's return on equity of -85.64% beat Codexis' return on equity.

Company Net Margins Return on Equity Return on Assets
Zenas BioPharmaN/A -85.64% -61.86%
Codexis -62.47%-90.51%-32.64%

In the previous week, Zenas BioPharma had 1 more articles in the media than Codexis. MarketBeat recorded 5 mentions for Zenas BioPharma and 4 mentions for Codexis. Zenas BioPharma's average media sentiment score of 0.97 beat Codexis' score of 0.26 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zenas BioPharma
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Codexis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Codexis has higher revenue and earnings than Zenas BioPharma. Codexis is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zenas BioPharma$10M110.55-$377.74M-$7.81N/A
Codexis$70.39M3.33-$43.97M-$0.52N/A

78.5% of Codexis shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 1.9% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Zenas BioPharma has a beta of -0.61, meaning that its stock price is 161% less volatile than the S&P 500. Comparatively, Codexis has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500.

Summary

Zenas BioPharma beats Codexis on 10 of the 16 factors compared between the two stocks.

How does Codexis compare to Geron?

Geron (NASDAQ:GERN) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Geron presently has a consensus target price of $2.17, indicating a potential upside of 48.40%. Codexis has a consensus target price of $5.00, indicating a potential upside of 93.80%. Given Codexis' higher probable upside, analysts plainly believe Codexis is more favorable than Geron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron
2 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Codexis
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Geron has a net margin of -46.65% compared to Codexis' net margin of -62.47%. Geron's return on equity of -28.86% beat Codexis' return on equity.

Company Net Margins Return on Equity Return on Assets
Geron-46.65% -28.86% -12.83%
Codexis -62.47%-90.51%-32.64%

In the previous week, Geron had 5 more articles in the media than Codexis. MarketBeat recorded 9 mentions for Geron and 4 mentions for Codexis. Codexis' average media sentiment score of 0.26 beat Geron's score of 0.22 indicating that Codexis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Geron
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Codexis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Codexis has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$183.88M5.09-$83.50M-$0.13N/A
Codexis$70.39M3.33-$43.97M-$0.52N/A

73.7% of Geron shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 1.9% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Geron has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Codexis has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500.

Summary

Geron beats Codexis on 8 of the 15 factors compared between the two stocks.

How does Codexis compare to MannKind?

Codexis (NASDAQ:CDXS) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Codexis currently has a consensus target price of $5.00, indicating a potential upside of 93.80%. MannKind has a consensus target price of $8.84, indicating a potential upside of 149.12%. Given MannKind's stronger consensus rating and higher possible upside, analysts plainly believe MannKind is more favorable than Codexis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Codexis
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
MannKind
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60

MannKind has a net margin of 1.68% compared to Codexis' net margin of -62.47%. MannKind's return on equity of -11.21% beat Codexis' return on equity.

Company Net Margins Return on Equity Return on Assets
Codexis-62.47% -90.51% -32.64%
MannKind 1.68%-11.21%1.11%

In the previous week, MannKind had 10 more articles in the media than Codexis. MarketBeat recorded 14 mentions for MannKind and 4 mentions for Codexis. Codexis' average media sentiment score of 0.26 beat MannKind's score of 0.24 indicating that Codexis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Codexis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
MannKind
3 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

MannKind has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codexis$70.39M3.33-$43.97M-$0.52N/A
MannKind$348.97M3.14$5.86M$0.02177.50

78.5% of Codexis shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 1.9% of Codexis shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Codexis has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500. Comparatively, MannKind has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Summary

MannKind beats Codexis on 12 of the 16 factors compared between the two stocks.

How does Codexis compare to OPKO Health?

Codexis (NASDAQ:CDXS) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Codexis presently has a consensus target price of $5.00, suggesting a potential upside of 93.80%. OPKO Health has a consensus target price of $1.55, suggesting a potential upside of 38.39%. Given Codexis' higher probable upside, equities research analysts plainly believe Codexis is more favorable than OPKO Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Codexis
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
OPKO Health
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.17

78.5% of Codexis shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 1.9% of Codexis shares are owned by insiders. Comparatively, 49.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, OPKO Health had 2 more articles in the media than Codexis. MarketBeat recorded 6 mentions for OPKO Health and 4 mentions for Codexis. OPKO Health's average media sentiment score of 1.08 beat Codexis' score of 0.26 indicating that OPKO Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Codexis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
OPKO Health
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Codexis has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Codexis has higher earnings, but lower revenue than OPKO Health. Codexis is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codexis$70.39M3.33-$43.97M-$0.52N/A
OPKO Health$606.90M1.39-$225.68M-$0.27N/A

OPKO Health has a net margin of -36.63% compared to Codexis' net margin of -62.47%. OPKO Health's return on equity of -16.78% beat Codexis' return on equity.

Company Net Margins Return on Equity Return on Assets
Codexis-62.47% -90.51% -32.64%
OPKO Health -36.63%-16.78%-10.98%

Summary

OPKO Health beats Codexis on 11 of the 17 factors compared between the two stocks.

How does Codexis compare to Ironwood Pharmaceuticals?

Codexis (NASDAQ:CDXS) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Ironwood Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Codexis$70.39M3.33-$43.97M-$0.52N/A
Ironwood Pharmaceuticals$296.15M2.30$24.02M$0.1332.08

Codexis has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.

Ironwood Pharmaceuticals has a net margin of 8.11% compared to Codexis' net margin of -62.47%. Ironwood Pharmaceuticals' return on equity of -13.72% beat Codexis' return on equity.

Company Net Margins Return on Equity Return on Assets
Codexis-62.47% -90.51% -32.64%
Ironwood Pharmaceuticals 8.11%-13.72%10.95%

Codexis presently has a consensus price target of $5.00, indicating a potential upside of 93.80%. Ironwood Pharmaceuticals has a consensus price target of $6.23, indicating a potential upside of 49.48%. Given Codexis' higher probable upside, equities analysts plainly believe Codexis is more favorable than Ironwood Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Codexis
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Ironwood Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.43

In the previous week, Ironwood Pharmaceuticals had 2 more articles in the media than Codexis. MarketBeat recorded 6 mentions for Ironwood Pharmaceuticals and 4 mentions for Codexis. Codexis' average media sentiment score of 0.26 beat Ironwood Pharmaceuticals' score of -0.29 indicating that Codexis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Codexis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ironwood Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

78.5% of Codexis shares are owned by institutional investors. 1.9% of Codexis shares are owned by insiders. Comparatively, 12.7% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Ironwood Pharmaceuticals beats Codexis on 12 of the 17 factors compared between the two stocks.

Get Codexis News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDXS vs. The Competition

Export
MetricCodexisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$234.52M$3.38B$6.22B$12.11B
Dividend YieldN/A2.23%2.74%5.26%
P/E Ratio-4.9634.8928.5627.26
Price / Sales3.33303.60535.5883.61
Price / CashN/A125.3043.3554.56
Price / Book4.617.169.936.90
Net Income-$43.97M$23.57M$3.54B$333.00M
7 Day Performance-8.51%2.79%1.57%1.87%
1 Month Performance30.30%6.24%6.12%8.63%
1 Year Performance13.16%79.27%43.02%43.19%

Codexis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CDXS
Codexis
2.8277 of 5 stars		$2.58
-3.0%		$5.00
+93.8%		+18.0%$234.52M$70.39MN/A250
ZBIO
Zenas BioPharma
3.6812 of 5 stars		$19.32
+10.1%		$44.14
+128.5%		+130.9%$1.01B$10MN/AN/A
GERN
Geron
2.1819 of 5 stars		$1.54
+2.0%		$2.17
+40.7%		+18.4%$967.76M$183.88MN/A70
MNKD
MannKind
3.6822 of 5 stars		$2.83
+2.9%		$8.69
+207.0%		-25.5%$849.19M$348.97M141.57400
OPK
OPKO Health
3.1296 of 5 stars		$1.13
+1.4%		$1.55
+37.8%		-12.5%$838.15M$606.90MN/A1,373

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CDXS) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel